Abstract
Surufatinib (Sulanda(R)), an oral angio-immuno kinase inhibitor that selectively targets VEGFR 1, 2, and 3, FGFR1 and CSF-1R, is being developed by HU......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
